NAFDAC DG Prof. Mojisola Adeyeye
The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the production of Chloroquine for clinical trials in the search for a cure for COVID-19.
Director-General of the agency, Mojisola Adeyeye, made the announcement on Friday at the NAFDAC headquarters in Lagos.
She, however, pointed out that NAFDAC is not approving Chloroquine for the treatment of COVID-19 but for clinical trials to find treatment for the virus.
“NAFDAC is not approving Chloroquine as a product that has can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.
“Therefore the medicine is being approved just for the clinical trials,” Adeyeye said.
She, therefore called on experts and researchers that are interested in doing a clinical trial on Chloroquine to approach approved outlets.
“Right now, we have asked one company to make a batch of Chloroquine for the purpose of clinical trial,” Adeyeye added.
She added that nobody should use Chloroquine as anti malaria.
